Are ketogenic diets promising for Alzheimer's disease? A translational review

被引:46
作者
Lilamand, Matthieu [1 ,2 ,3 ,4 ]
Porte, Baptiste [1 ,2 ]
Cognat, Emmanuel [1 ,2 ]
Hugon, Jacques [1 ,2 ]
Mouton-Liger, Francois [1 ,2 ]
Paquet, Claire [1 ,2 ]
机构
[1] Univ Paris, INSERM, U1144, Optimisat Therapeut Neuropsychopharmacol, Paris, France
[2] Nord Univ Paris, Lariboisiere Hosp, APHP, CMRR Paris Nord Ile France,Ctr Neurol Cognit, 200 Rue Faubourg, F-75010 Paris, France
[3] APHP Nord Univ Paris, Dept Geriatr, Bichat, Bretonneau Hospitals, F-75018 Paris, France
[4] Nord Univ Paris, Bichat & Bretonneau Hosp, APHP, Dept Geriatr, F-75018 Paris, France
关键词
Ketogenic diet; Alzheimer's disease; Brain metabolism; Animal models; MOUSE MODEL; COGNITIVE IMPAIRMENT; BETA-HYDROXYBUTYRATE; KETONE ESTER; SUPPLEMENTATION; METABOLISM; MITOCHONDRIA; MEMORY;
D O I
10.1186/s13195-020-00615-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Brain amyloid deposition and neurofibrillary tangles in Alzheimer's disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolism is closely related to neuroinflammation. Ketogenic diets (KDs) include a high amount of fat, low carbohydrate and medium-chain triglyceride (MCT) intake. KDs lead to the production of ketone bodies to fuel the brain, in the absence of glucose. These nutritional interventions are validated treatments of pharmacoresistant epilepsy, consequently leading to a better intellectual development in epileptic children. In neurodegenerative diseases and cognitive decline, potential benefits of KD were previously pointed out, but the published evidence remains scarce. The main objective of this review was to critically examine the evidence regarding KD or MCT intake effects both in AD and ageing animal models and in humans. Main body We conducted a review based on a systematic search of interventional trials published from January 2000 to March 2019 found on MEDLINE and Cochrane databases. Overall, 11 animal and 11 human studies were included in the present review. In preclinical studies, this review revealed an improvement of cognition and motor function in AD mouse model and ageing animals. However, the KD and ketone supplementation were also associated with significant weight loss. In human studies, most of the published articles showed a significant improvement of cognitive outcomes (global cognition, memory and executive functions) with ketone supplementation or KD, regardless of the severity of cognitive impairments previously detected. Both interventions seemed acceptable and efficient to achieve ketosis. Conclusion The KD or MCT intake might be promising ways to alter cognitive symptoms in AD, especially at the prodromal stage of the disease. The need for efficient disease-modifying strategies suggests to pursue further KD interventional studies to assess the efficacy, the adherence to this diet and the potential adverse effects of these nutritional approaches.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Some promising medicinal plants used in Alzheimer's disease: an ethnopharmacological perspective
    Bordoloi, Smita
    Pathak, Kalyani
    Devi, Mary
    Saikia, Riya
    Das, Jyotirmoy
    Kashyap, Vikrant Hari
    Das, Dibyajyoti
    Ahmad, Mohammad Zaki
    Abdel-Wahab, Basel A.
    DISCOVER APPLIED SCIENCES, 2024, 6 (05)
  • [42] The use of ketogenic diets in cancer patients: a systematic review
    Maximilian Römer
    Jennifer Dörfler
    Jutta Huebner
    Clinical and Experimental Medicine, 2021, 21 : 501 - 536
  • [43] The use of ketogenic diets in cancer patients: a systematic review
    Roemer, Maximilian
    Doerfler, Jennifer
    Huebner, Jutta
    CLINICAL AND EXPERIMENTAL MEDICINE, 2021, 21 (04) : 501 - 536
  • [44] Ketogenic β-hydroxybutyrate regulates β-hydroxybutyrylation of TCA cycle-associated enzymes and attenuates disease-associated pathologies in Alzheimer's mice
    Han, Wanhong
    Zhang, Bingchang
    Zhao, Wenpeng
    Zhao, Wentao
    He, Jiawei
    Qiu, Xiansheng
    Zhang, Liang
    Wang, Xiuyan
    Wang, Yong
    Lu, Hanwen
    Zhang, Yaya
    Xie, Yuanyuan
    Geng, Yanyan
    Zhao, Wujie
    Huang, Qionghui
    Zhang, Yun-wu
    Wang, Zhanxiang
    AGING CELL, 2025, 24 (01)
  • [45] American Ginseng for the Treatment of Alzheimer's Disease: A Review
    Shan, Mengyao
    Bai, Yunfan
    Fang, Xiaoxue
    Lan, Xintian
    Zhang, Yegang
    Cao, Yiming
    Zhu, Difu
    Luo, Haoming
    MOLECULES, 2023, 28 (15):
  • [46] Hippocampus and its involvement in Alzheimer's disease: a review
    Rao, Y. Lakshmisha
    Ganaraja, B.
    Murlimanju, B., V
    Joy, Teresa
    Krishnamurthy, Ashwin
    Agrawal, Amit
    3 BIOTECH, 2022, 12 (02)
  • [47] Impaired Resolition of Inflammation in Alzheimer's Disease: A Review
    Whittington, Robert A.
    Planel, Emmanuel
    Terrando, Niccolo
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [48] Emerging concepts towards a translational framework in Alzheimer's disease
    Cozachenco, Danielle
    Zimmer, Eduardo R.
    Lourenco, Mychael, V
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2023, 152
  • [49] Positron Emission Tomography in Animal Models of Alzheimer's Disease Amyloidosis: Translational Implications
    Ni, Ruiqing
    PHARMACEUTICALS, 2021, 14 (11)
  • [50] Alzheimer's disease drug development: translational neuroscience strategies
    Cummings, Jeffrey L.
    Banks, Sarah J.
    Gary, Ronald K.
    Kinney, Jefferson W.
    Lombardo, Joseph M.
    Walsh, Ryan R.
    Zhong, Kate
    CNS SPECTRUMS, 2013, 18 (03) : 128 - 138